跳至主要内容
临床试验/EUCTR2004-001930-18-EE
EUCTR2004-001930-18-EE进行中(未招募)不适用

A MULTI-CENTER, RANDOMIZED, BLINDED STUDY COMPARING THE EFFECT OF CRx-102 PLUS DMARD THERAPY TO THAT OF PLACEBO PLUS DMARD THERAPY ON SERUM C-REACTIVE PROTEIN (CRP) AND CYTOKINES IN SUBJECTS WITH RHEUMATOID ARTHRITIS - CRx-102-RA

CombinatoRx, Inc0 个研究点目标入组 60 人开始时间: 2006年1月19日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Subject must be at least 18 years of age.
  • Have rheumatoid arthritis.
  • Have at least 3 swollen joints (max = 28) and 3 tender joints (max = 28).
  • Subject must have baseline C-reactive protein levels of at least 2.2 mg/L and a DAS28 score greater than 4.5.
  • Subject must have been on DMARD therapy for at least 3 months and be on a stable dose of DMARD therapy for at least 28 days prior to enrollment.
  • Subject must have voluntarily signed the informed consent
  • Are the trial subjects under 18?
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Female subject is pregnant or lactating or of child bearing potential not using acceptable methods of birth control (barriers or abstinence). Female subjects using hormonal birth control are not to be enrolled.
  • Subject is currently taking any steroids (glucocorticoids). All glucocorticoids must be discontinued for at least one month prior to entering study. Intraarticular, intramuscular, or intravenous glucocorticoids must not have been given at least 6 weeks prior to entering the study.
  • Subject is currently taking more than 81 mg of aspirin daily.
  • Subject is currently taking a statin, unless she/he has been on a stable dose of the same statin for at least 3 months prior to entering into the trial.
  • Subject has any active infections or recent surgical procedures within 30 days of study initiation.
  • Subject has uncontrolled diabetes mellitus as defined by a HbA1C value = 7.0%.
  • Subject knowingly has HIV or Hepatitis.
  • Subject has undergone administration of any investigational drug within 30 days of study initiation.
  • Subject has a history of hypersensitivity to steroids and/or dipyridamole.
  • Subject has limited mental capacity or language skills such that simple instructions cannot be followed or information regarding adverse events cannot be provided.

研究者

相似试验

进行中(未招募)
不适用
A MULTI-CENTER, RANDOMIZED, BLINDED STUDY COMPARING THE EFFECT OF CRx-150 PLUS DMARD THERAPY TO THAT OF PLACEBO PLUS DMARD THERAPY ON SERUM C-REACTIVE PROTEIN (CRP) AND CYTOKINES IN SUBJECTS WITH RHEUMATOID ARTHRITIS. - CRx-150-RARHEUMATOID ARTHRITIS
EUCTR2004-001490-26-EECombinatoRx, Inc72
已完成
4 期
A MULTICENTER RANDOMIZED CONTROLLED STUDY COMPARING EARLY IMPLANT PLACEMENT TO ALVEOLAR RIDGE PRESERVATION FOR SINGLE TOOTH REPLACEMENT IN THE ANTERIOR AREAK00-K14Diseases of oral cavity, salivary glands and jaws
DRKS00018875Clinic of Reconstructive DentistryCenter of Dental MedicineUniversity Zurich47
已完成
不适用
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO COMPARE THE EFFICACY AND SAFETYOF CADAZOLID VERSUS VANCOMYCIN IN SUBJECTS WITH CLOSTRIDIUM DIFFICILE-ASSOCIATEDDIARRHEA (CDAD)-A047 Enterocolitis due to Clostridium difficileEnterocolitis due to Clostridium difficileA047
PER-087-13Actelion Pharmaceuticals Ltd,1
未知
不适用
A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS TO ORAL SOLITHROMYCIN (CEM-101) COMPARED TO INTRAVENOUS TO ORAL MOXIFLOXACIN IN THE TREATMENT OF ADULT PATIENTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA.-J159 Bacterial pneumonia, unspecifiedBacterial pneumonia, unspecifiedJ159
PER-028-14Cempra Pharmaceuticals, Inc.,9
已完成
不适用
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE CLINICAL EFFECTS OF MONTELUKAST INTRAVENOUS WITH PLACEBO IN PEDIATRIC PATIENTS (BETWEEN 6 AND 14 YEARS OLD) WHO SUFFER FROM ACUTE ASTHMA-J459 Asthma, unspecifiedAsthma, unspecifiedJ459
PER-028-05MERCK & CO.INC.,